Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4786730
Max Phase: Preclinical
Molecular Formula: C21H30O7
Molecular Weight: 394.46
Molecule Type: Unknown
Associated Items:
ID: ALA4786730
Max Phase: Preclinical
Molecular Formula: C21H30O7
Molecular Weight: 394.46
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COC(=O)[C@]1(C)[C@@H]2C(=O)[C@H](O)[C@H]3[C@@H](C)/C(=C/C(=O)O)CC[C@@H]3[C@@]2(C)CC[C@@H]1O
Standard InChI: InChI=1S/C21H30O7/c1-10-11(9-14(23)24)5-6-12-15(10)16(25)17(26)18-20(12,2)8-7-13(22)21(18,3)19(27)28-4/h9-10,12-13,15-16,18,22,25H,5-8H2,1-4H3,(H,23,24)/b11-9+/t10-,12-,13-,15-,16+,18+,20+,21-/m0/s1
Standard InChI Key: SPSFGGYXNQLASU-DIOQFOCFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 394.46 | Molecular Weight (Monoisotopic): 394.1992 | AlogP: 1.56 | #Rotatable Bonds: 2 |
Polar Surface Area: 121.13 | Molecular Species: ACID | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.27 | CX Basic pKa: | CX LogP: 1.60 | CX LogD: -1.38 |
Aromatic Rings: 0 | Heavy Atoms: 28 | QED Weighted: 0.48 | Np Likeness Score: 2.64 |
1. Vo PHT,Nguyen TDT,Tran HT,Nguyen YN,Doan MT,Nguyen PH,Lien GTK,To DC,Tran MH. (2021) Cytotoxic components from the leaves of Erythrophleum fordii induce human acute leukemia cell apoptosis through caspase 3 activation and PARP cleavage., 31 [PMID:33161122] [10.1016/j.bmcl.2020.127673] |
Source(1):